Article
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis.
Targeted oncology - 1 Jun 2020
Chen Ya, Wang Shuyuan, Zhang Bo, Zhao Yiming, Zhang Lele, Hu Minjuan, Zhang Wei, Han Baohui
Abstract excerpt
BACKGROUND: Osimertinib is a standard therapy for advanced non-small cell lung cancer (NSCLC) patients with an acquired epidermal growth factor receptor (EGFR) T790M mutation; however, the exploration of clinical characteristics that may affect prognosis and long-term survival is still lacking. OBJECTIVE: This retrospective study aimed to provide long-term survival data and explore meaningful prognostic factors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.